Shares of Momenta Pharmaceuticals (MNTA) crash 23% immediately after the FDA announces it has...

This news story has 2 comments:

Register or Login to rate comments »

User 312235 Comments (2)
 
Very strong company, with great pipeline.
Will bounce back big-time.
19 Sep 2011, 12:43 PM Reply Like

kaalia Comments (2)
 
at full capacity 40% share of enoxaparin market. Surely Teva/ Amphastar can take another 40% of the market. I do not see topline share of Sandoz going down, though the royalties to Momenta will come down significantly. But then Momenta is sitting on 300m$ cash and a 300m$ valuation of the cash flow of reduced royalties. In addition a possibility to launch Copaxone generic should enable it to sustain a market cap of approx. 750m$. I conservatively see a target price of 14$/ share in next 3 months.
20 Sep 2011, 03:57 PM Reply Like